Interview: Qiu Jiazhou – MD Chairman, H-Guard, China
Dr. Qiu, could you please introduce your company, H-Guard, to our international readers? “It is clear that our efforts and investments over the past five years have paid off. Just…
Founded in August 2013 by four returnees scientists and entrepreneurs, H-Guard is a high-tech enterprise integrating the R&D, production and sales of medical devices.
Having introduced a number of international leading biomedical projects and in vitro diagnostic projects from the United States, our flagship product is the latest in vitro diagnostic kit for early warning of myocardial infarction and cerebral infarction risk. We are also developing other POCT cardiovascular disease diagnostic reagents and have core material production technology.
Address | #604, Building 1, Shenzhen Biomedicine Innovations Industry Park, 14 Jinhui Road, Pingshan District, Shenzhen, PRC |
Tel | +86 755 8945 9910 |
Website | http://www.h-guard.com.cn/ |
ivd@h-guard.com.cn |
Dr. Qiu, could you please introduce your company, H-Guard, to our international readers? “It is clear that our efforts and investments over the past five years have paid off. Just…
Amid geopolitical tensions and a drop in foreign investments, China continues to encourage international companies to increase their Chinese footprint. At this week’s China Development Forum (CDF), CEOs from Pfizer,…
The latest news from Chinese pharma, including progress on the US Senate bill targeting BGI and WuXi AppTec, a report on why drug research is slowing in the country, and…
No longer a fledgling biotech, oncology-focused BeiGene, originally created in China in 2010 with the idea of carrying out world-class research there, has since expanded its global reach and garnered…
US Congress has highlighted Chinese biotechnology firms, including giants WuXi and BGI, as posing a risk to the country’s national security. PharmaBoardroom takes a look at why the US is…
The biggest pharma industry stories coming out of China, including the impact of the US Biosecure act on Chinese giants WuXi AppTec and WuXi Bio; Novartis’ acquisition of SanReno Therapeutics;…
Two leading regional pharma executives, from Eli Lilly and Boehringer Ingelheim respectively have recently moved to head up China operations; perhaps a sign that despite recent geopolitical tensions, multinational biopharma…
The latest pharma industry and healthcare news coming out of China including AstraZeneca’s acquisition of Gracell Biotechnologies; the alarming drop in enrolment in China’s state health insurance system; Huadong Medicine/Impact…
Hong Kong Exchanges and Clearing Limited (HKEX) chief executive Nicolas Aguzin has stepped down after a term fraught with upheaval. Having survived COVID-19 isolation, under Aguzin HKEX was confronted with…
The APAC region —with an approximate ten percent growth in trial numbers between 2017 and 2022— is rapidly becoming the world’s leading market for clinical trials. Karen Chu, CEO of…
Harvest Integrated Research Organization (HiRO) is a CRO that serves both Asian biotechs looking to do clinical trials outside of the region, and US and European clients wanting to conduct…
A roundup of some of the biggest news stories from the pharma industry in China including Aspen’s purchase of Sandoz’s Chinese business; Moderna’s first mRNA facility in China; WuXi Biologics’…
Although well-established as Asia’s leading financial services and trading hub, Hong Kong has never truly been globally competitive in the innovation and technology space, despite piecemeal initiatives to bolster its…
See our Cookie Privacy Policy Here